Gossamer Bio, Inc. (NASDAQ:GOSS) is expected to report third quarter earnings results, after market close, on Tuesday 10th November 2020.
Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.85 per share.
Looking ahead, the full year loss are expected at $ 3.58 per share.
Stock Performance
Shares of Gossamer Bio, Inc. traded up $ 0.64 or 7.42 percent on Monday, reaching $ 9.27 with volume of 628.20 thousand shares. Gossamer Bio, Inc. has traded high as $ 9.49 and has cracked $ 8.89 on the downward trend
According to the previous trading day, closing price of $ 9.27, representing a 14.76 % increase from the 52 week low of $ 7.52 and a 68.21 % decrease over the 52 week high of $ 27.15.
The company has a market capital of $ 667.34 million and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 19th October 2020, maintained by HC Wainwright at Buy rating, with $ 15.00 target price.
- On 14th October 2020, maintained by Cantor Fitzgerald at Overweight rating, with $ 20.00 target price.
- On 13th October 2020, maintained by SVB Leerink at Outperform rating, with $ 29.00 target price.
Conference Call
Gossamer Bio, Inc. will be hosting a conference call at 4:30 PM eastern time on 10th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.gossamerbio.com
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2 that is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma, as well as that has completed Phase I clinical trial for chronic rhinosinusitis with nasal polyps, without nasal polyps, and chronic spontaneous urticarial; GB002, a platelet-derived growth factor, receptor kinase inhibitor that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension; GB004, an oral small molecule that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and GB1275, an oral small molecule for the treatment of oncology indications. It has license agreement with Pulmokine, Inc.
